Pharmacokinetics and immunogenicity of a recombinant human butyrylcholinesterase bioscavenger in macaques following intravenous and pulmonary delivery

被引:12
|
作者
Rosenberg, Yvonne J. [1 ]
Adams, Robert J. [2 ]
Hernandez-Abanto, Segundo [1 ]
Jiang, Xiaoming [1 ]
Sun, Wei [3 ]
Mao, Lingjun [1 ]
Lee, K. David [1 ]
机构
[1] PlantVax Inc, Rockville, MD 20850 USA
[2] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA
[3] Walter Reed Army Inst Res, Div Biochem, Silver Spring, MD 20910 USA
基金
美国国家卫生研究院;
关键词
Human butyrylcholinesterase; Pharmacokinetics; Immunogenicity; Aerosol delivery; Monkey model; Animal Rule; HUMAN SERUM BUTYRYLCHOLINESTERASE; N-GLYCOLYLNEURAMINIC ACID; PROTECTION; TOXICITY; ACETYLCHOLINESTERASE; MODEL; SOMAN; PRETREATMENT; STABILITY; PRODUCTS;
D O I
10.1016/j.cbi.2015.09.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant (r) and native butyrylcholinesterse (BChE) are potent bioscavengers of organophosphates (OPs) such as nerve agents and pesticides and are undergoing development as antidotal treatments for OP-induced toxicity. Because of the lethal properties of such agents, regulatory approval will require extensive testing under the Animal Rule. However, human (Hu) glycoprotein biologicals, such as BChE, present a challenge for assessing immunogenicity and efficacy in heterologous animal models since any immune responses to the small species differences in amino acids or glycans between the host and biologic may alter pharmacodynamics and preclude accurate efficacy testing; possibly underestimating their potential protective value in humans. To establish accurate pharmacokinetic and efficacy data, an homologous animal model has been developed in which native and PEGylated forms of CHO-derived rMaBChE were multiply injected into homologous macaques with no induction of antibody. These now serve as controls for assessing the pharmacokinetics and immunogenicity in macaques of multiple administrations of PEGylated and unmodified human rBChE (rHuBChE) by both intravenous (IV) and pulmonary routes. The results indicate that, except for maximal concentration (Cmax), the pharmacokinetic parameters following IV injection with heterologous PEG-rHuBChE were greatly reduced even after the first injection compared with homologous PEG-rMaBChE. Anti-HuBChE antibody responses were induced in all monkeys after the second and third administrations regardless of the route of delivery; impacting rates of clearance and usually resulting in reduced endogenous MaBChE activity. These data highlight the difficulties inherent in assessing pharmacokinetics and immunogenicity in animal models, but bode well for the efficacy and safety of rHuBChE pretreatments in homologous humans. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 50 条
  • [41] Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats
    Miyaji, Y.
    Kurihara, A.
    Kamiyama, E.
    Shiiki, T.
    Kawai, K.
    Okazaki, O.
    XENOBIOTICA, 2009, 39 (02) : 113 - 124
  • [42] Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats
    Ait-Oudhia, Sihem
    Scherrmann, Jean-Michel
    Krzyzanski, Wojciech
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03): : 897 - 910
  • [43] Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX™ adjuvanted recombinant antigens
    Vujanic, Ana
    Wee, Janet L. K.
    Snibson, Kenneth J.
    Edwards, Stirling
    Pearse, Martin
    Quinn, Charles
    Moloney, Margaret
    Taylor, Shirley
    Scheerlinck, Jean-Pierre Y.
    Sutton, Philip
    VACCINE, 2010, 28 (14) : 2593 - 2597
  • [44] A COMPARATIVE-STUDY ON THE PULMONARY DELIVERY OF TOBRAMYCIN ENCAPSULATED INTO LIPOSOMES AND PLA MICROSPHERES FOLLOWING INTRAVENOUS AND ENDOTRACHEAL DELIVERY
    POYNER, EA
    ALPAR, HO
    ALMEIDA, AJ
    GAMBLE, MD
    BROWN, MRW
    JOURNAL OF CONTROLLED RELEASE, 1995, 35 (01) : 41 - 48
  • [45] Stabilized plasmid-lipid particles: Pharmacokinetics and plasmid delivery to distal tumors following intravenous injection
    Monck, MA
    Mori, A
    Lee, D
    Tam, P
    Wheeler, JJ
    Cullis, PR
    Scherrer, P
    JOURNAL OF DRUG TARGETING, 2000, 7 (06) : 439 - 452
  • [46] PHARMACOKINETICS AND BIOAVAILABILITY OF HYDROMORPHONE FOLLOWING INTRAVENOUS AND ORAL-ADMINISTRATION TO HUMAN-SUBJECTS
    VALLNER, JJ
    STEWART, JT
    KOTZAN, JA
    KIRSTEN, EB
    HONIGBERG, IL
    JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (04): : 152 - 156
  • [47] Impact of protein aggregation on the immunogenicity of a human monoclonal antibody following pulmonary administration in mice
    Mahri, Sohaib
    Cassiers, Celine
    Gracin, Sandra
    Tyteca, Donatienne
    Uwambayinema, Francine
    Huaux, Francois
    Ibrahim, Mariam
    Piper, Sian
    Llinas, Antonio
    Friden, Markus
    Vanbever, Rita
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 667
  • [48] Sustained high level expression of human FIX following liver targeted delivery of recombinant adeno-associated virus encoding the human FIX gene in rhesus macaques.
    Nathwani, AC
    Davidoff, AM
    Hanawa, H
    Hu, YY
    Lozier, JN
    Hoffer, F
    Nikanorov, A
    Vanin, EF
    Slaughter, C
    Mandrell, TD
    Nienhuis, AW
    BLOOD, 2001, 98 (11) : 782A - 782A
  • [49] PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF RECOMBINANT INTERFERON ALPHA-A IN MONKEYS - COMPARISON OF INTRAVENOUS, INTRAMUSCULAR, AND INTRAVENTRICULAR DELIVERY
    COLLINS, JM
    RICCARDI, R
    TROWN, P
    ONEILL, D
    POPLACK, DG
    CANCER DRUG DELIVERY, 1985, 2 (04): : 247 - 253
  • [50] THE TOXICITY OF RECOMBINANT HUMAN INTERLEUKIN-2 IN RATS FOLLOWING INTRAVENOUS-INFUSION
    MATORY, Y
    CHANG, A
    LIPFORD, N
    BRAZIEL, R
    ROSENBERG, S
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 304 - 304